文献速递心律失常

PRAGUE-17 试验 4 年随访:左心耳封堵对比非华法林口服抗凝

4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2021-11-05

PRAGUE-17 随机非劣效试验将 402 例高卒中/出血风险房颤患者分配至经皮左心耳封堵(LAAC)或非华法林直接口服抗凝药(DOAC,95% 为阿哌沙班)。中位随访 3.5 年(1354 患者年)显示,LAAC 在主要复合终点上非劣于 DOAC,且非手术相关临床相关出血显著减少。

要点

  • LAAC 在主要复合终点(心源性栓塞、心血管死亡、临床相关出血、手术/器械并发症)非劣于 DOAC。
  • LAAC 组非手术相关临床相关出血风险显著低于 DOAC 组(sHR 0.55,95%CI 0.31-0.97,P=0.039)。
  • 全卒中/短暂性脑缺血发作、心血管死亡、临床相关出血的组件终点组间差异无统计学意义。

核心结论

  • 长期随访中 LAAC 在预防主要心血管、神经或出血事件方面仍非劣于 DOAC。
  • LAAC 显著减少非手术相关临床相关出血。

研究设计与样本

  • PRAGUE-17 为随机非劣效试验,比较经皮 LAAC(Watchman 或 Amulet)与 DOAC(95% 阿哌沙班)。
  • 纳入非瓣膜性房颤患者,具备心源性栓塞史、临床相关出血史,或 CHA2DS2-VASc≥3 且 HASBLED≥2。
  • 共随机 402 例(每组 201 例),年龄 73.3±7.0 岁,男性 65.7%,CHA2DS2-VASc 4.7±1.5,HASBLED 3.1±0.9。
  • 主要分析为改良意向治疗,中位随访 3.5 年(1354 患者年)。

主要发现

  • 主要复合终点:sHR 0.81(95%CI 0.56-1.18,P=0.27),非劣效 P=0.006。
  • 心血管死亡:sHR 0.68(95%CI 0.39-1.20,P=0.19)。
  • 全卒中/短暂性脑缺血发作:sHR 1.14(95%CI 0.56-2.30,P=0.72)。
  • 临床相关出血:sHR 0.75(95%CI 0.44-1.27,P=0.28)。
  • 非手术相关临床相关出血:sHR 0.55(95%CI 0.31-0.97,P=0.039)。

关键数值与推荐

  • 主要终点为非劣效设计,非劣效 P=0.006。
  • 非手术相关临床相关出血 sHR 0.55(95%CI 0.31-0.97,P=0.039)。

临床怎么用

  • 对于高卒中及出血风险的非瓣膜性房颤患者,LAAC 可作为 DOAC 的长期替代策略。
  • LAAC 在减少非手术相关临床相关出血方面具有优势,可用于出血风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PRAGUE-17 (Left Atrial Appendage Closure vs Novel Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) was noninferior to nonwarfarin direct oral anticoagulants (DOACs) for preventing major neurological, cardiovascular, or bleeding events in patients with atrial fibrillation (AF) who were at high risk. OBJECTIVES: This study sought to assess the prespecified long-term (4-year) outcomes in PRAGUE-17. METHODS: PRAGUE-17 was a randomized noninferiority trial comparing percutaneous LAAC (Watchman or Amulet) with DOACs (95% apixaban) in patients with nonvalvular AF and with a history of cardioembolism, clinically-relevant bleeding, or both CHA2DS2-VASc ≥3 and HASBLED ≥2. The primary endpoint was a composite of cardioembolic events (stroke, transient ischemic attack, or systemic embolism), cardiovascular death, clinically relevant bleeding, or procedure-/device-related complications (LAAC group only). The primary analysis was modified intention-to-treat. RESULTS: This study randomized 402 patients with AF (201 per group, age 73.3 ± 7.0 years, 65.7% male, CHA2DS2-VASc 4.7 ±1.5, HASBLED 3.1 ± 0.9). After 3.5 years median follow-up (1,354 patient-years), LAAC was noninferior to DOACs for the primary endpoint by modified intention-to-treat (subdistribution HR [sHR]: 0.81; 95% CI: 0.56-1.18; P = 0.27; P for noninferiority = 0.006). For the components of the composite endpoint, the corresponding sHRs were 0.68 (95% CI: 0.39-1.20; P = 0.19) for cardiovascular death, 1.14 (95% CI: 0.56-2.30; P = 0.72) for all-stroke/transient ischemic attack, 0.75 (95% CI: 0.44-1.27; P = 0.28) for clinically relevant bleeding, and 0.55 (95% CI: 0.31-0.97; P = 0.039) for nonprocedural clinically relevant bleeding. The primary endpoint outcomes were similar in the per-protocol (sHR: 0.80; 95% CI: 0.54-1.18; P = 0.25) and on-treatment (sHR: 0.82; 95% CI: 0.56-1.20; P = 0.30) analyses. CONCLUSIONS: In long-term follow-up of PRAGUE-17, LAAC remains noninferior to DOACs for preventing major cardiovascular, neurological, or bleeding events. Furthermore, nonprocedural bleeding was significantly reduced with LAAC. (PRAGUE-17 [Left Atrial Appendage Closure vs Novel Anticoagulation Agents in Atrial Fibrillation]; NCT02426944).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Osmancik, Herman, Neuzil, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2021. PMID: 34748929. doi:10.1016/j.jacc.2021.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。